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Abstract
The metabolic insults associated with diabetes lead to low-grade chronic inflammation, retinal 
endothelial cell damage, and inadequate vascular repair. This is partly due to the increased 
activation of bone marrow (BM)-derived proinflammatory monocytes infiltrating the retina, and 
the compromised function of BM-derived reparative circulating angiogenic cells (CACs), which 
home to sites of endothelial injury and foster vascular repair. We now propose that a metabolic 
link leading to activated monocytes and dysfunctional CACs in diabetes involves upregulation of a 
central enzyme of sphingolipid signaling, acid sphingomyelinase (ASM). Selective inhibition of 
ASM in the BM prevented diabetes-induced activation of BM-derived microglia-like cells and 
normalized proinflammatory cytokine levels in the retina. ASM upregulation in diabetic CACs 
caused accumulation of ceramide on their cell membrane, thereby reducing membrane fluidity and 
impairing CAC migration. Replacing sphingomyelin with ceramide in synthetic membrane 
vesicles caused a similar decrease in membrane fluidity. Inhibition of ASM in diabetic CACs 
improved membrane fluidity and homing of these cells to damaged retinal vessels. Collectively, 
these findings indicate that selective modulation of sphingolipid metabolism in BM-derived cell 
populations in diabetes normalizes the reparative/proinflammatory cell balance and can be 
explored as a novel therapeutic strategy for treating diabetic retinopathy.
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Diabetic retinopathy (DR) is a sight-threatening complication of diabetes. Available DR 
treatment options are highly invasive and only help to slow progression of the disease. 
Hyperglycemia and dyslipidemia are major metabolic abnormalities in diabetes. Molecular 
pathogenesis of hyperglycemia and dyslipidemia-induced damage to the retina is not clear 
but may involve several mechanisms including oxidative stress, activation of protein kinase 
C, accumulation of polyols, and advanced glycation end-products, endoplasmic reticulum 
(ER) stress, and chronic low-grade inflammation [1, 2]. Although clinical manifestations of 
DR are due to vascular abnormalities including increased microvascular permeability, vessel 
leakage, microaneurysms formation, and eventually capillary drop-out, and pathological 
neovascularization [1], recent studies demonstrated that most retinal cell types contribute to 
pathogenesis of the disease. Activated retinal glial cells and pigment epithelial cells in 
diabetes express proinflammatory cytokines and vascular endothelial growth factor (VEGF), 
contributing to damage of endothelial cells lining the retinal vasculature [3–5]. Impaired 
retinal insulin receptor signaling contributes to metabolic stress to neurons, which may in 
turn impair blood-retinal barrier integrity [6].
In addition to direct effects on the retina, hyperglycemia and dyslipidemia can indirectly 
affect the retina through the induction of bone marrow (BM) pathology. Hematopoietic stem 
cells (HSC) in the BM give rise to lymphoid and myeloid progenitors that differentiate into 
blood cells. BM pathology in diabetes is proposed to cause activation of circulating 
myelomonocytic cells, leading to increased leukocyte adhesion, which contributes to retinal 
inflammation [6, 7]. Several studies have found that myeloid-derived monocytes can 
infiltrate the diabetic retina, adopt a microglia-like phenotype, and exacerbate inflammation 
by secreting proinflammatory cytokines. This cytokine secretion can further activate resident 
microglia, astrocytes, and Müller glia in the retina [5, 8, 9].
We have previously demonstrated that, in addition to increase in proinflammatory 
leukocytes, diabetes induces a reduction of vascular reparative cells [10, 11]. Circulating 
angiogenic cells (CACs) are BM-derived vascular reparative cells known to be exquisitely 
sensitive to the diabetic milieu [12–14]. Release of CACs from BM into circulation and 
extravasation into tissues is a critical component of their physiological role as reparative 
cells. Indeed, there is growing interest in understanding stem/progenitor cell migration and 
developing interventions that increase homing efficiency of CACs to sites of tissue damage 
[14–17]. Recent studies indicate that CACs isolated from diabetic individuals are ineffective 
at vascular regeneration due to reduced migratory and proliferation abilities [12, 14, 15]. We 
recently demonstrated that reduced deformability of human CACs in diabetes is linked to 
decrease in migratory prowess of these cells [14]. Thus, modulating cell deformability can 
provide a way of improving mobilization efficiency of CACs to sites of vascular injury.
The individual molecular steps causing retinal inflammation and impaired vascular repair are 
not well-understood but probably involve hyperglycemia and dyslipidemia associated with 
diabetes. Clinical studies have demonstrated strong associations between dyslipidemia and 
development of DR [18, 19]. Bioactive sphingolipid metabolites like ceramide, 
glycosphingolipids, and sphingosine 1-phosphate (S1P) are believed to play crucial roles in 
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development of DR [20–24]. Acid sphingomyelinase (ASM), the enzyme converting 
sphingomyelin to ceramide, is a key element activated by diabetes in both CACs and retinal 
vasculature. We have previously shown that ASM is important for cytokine signaling in 
retinal endothelial cells, and that inhibition of ASM prevents retinal inflammation and 
vascular degeneration associated with diabetes [13, 20, 25]. In this report, we describe a link 
between increased ASM activity in the BM cells and shift in BM-derived inflammatory and 
reparative cell function in the diabetic retina.
Materials and Methods
Mice
All procedures involving animal models were approved by Institutional Animal Care and 
Use Committee at MSU. Male C57BL/6J and C57BL/6-Tg(CAG-EGFP) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME, http://www.jax.org) and made 
diabetic by injections of 55 mg streptozotocin (STZ) (Sigma Aldrich, St. Louis, http://
www.sigmaaldrich.com) per kg body weight for five consecutive days. Insulin (0–2 units per 
day) was administered to prevent acute weight loss, while maintaining hyperglycemia (~20 
mmol/L blood glucose).
Generation of ASM−/−, ASM−/− × gfp+, and gfp+ Chimeras
ASM−/− mice used as donor strain were obtained from Dr. Kolesnick (with permission of Dr. 
Schuchman), and C57BL/6-Tg(CAG-EGFP) transgenic donor strain from Jackson 
Laboratory. C57BL/6.ASM−/−, C57BL/6.gfp+, and C57BL/6.ASM−/− × gfp+ chimeras were 
generated by irradiating recipient 8-weeks old C57BL/6 mice with 1,100 rads followed by 
retroorbital injection of BM (2 × 106 cells) from donor mice. Wild-type (WT) BM donor 
cells transferred into WT recipient chimeras were used as control.
Retinal Vascular Permeability
In vivo retinal vascular permeability was assessed after tail vein injections of fluorescein 
isothiocyanate (FITC)-labeled albumin 20 mg/kg (Sigma-Aldrich), as described previously 
[26]. Images of flat-mounted retinas were captured using Olympus FluoView 1000 Laser 
Scanning confocal microscope. Retinas were disrupted mechanically and cleared by 
centrifugation. FITC-albumin in supernatant was quantified using spectrofluorometer and 
normalized to plasma fluorescence.
Acellular Capillaries
Mice eyes were enucleated, and retinal vasculature was isolated by elastase digestion [20]. 
Retinal vasculature was stained with hematoxylin and eosin. Acellular capillaries in 
midretina were systematically counted by three investigators as described previously [20]. 
All samples were analyzed in a masked manner.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted from mice retinas and quantitative reverse transcriptase 
polymerase chain reaction (RT-PCR) was performed as described previously [20]. Mouse 
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gene-specific primers for ASM, intercellular adhesion molecule (ICAM-1), vascular cell 
adhesion molecule (VCAM-1), VEGF A, and interleukin 1β (IL-1β) were used. All results 
were normalized to cyclophilin.
Western Blot Analysis
Protein extraction and Western blot analysis were performed as previously described [20]. 
Anti-ASM primary antibody (Cell Signaling Technology, Beverly, MA, http://
www.cellsignal.com, 1:1,000 dilution) followed by Alexa-Fluor secondary antibody (Life 
Technologies, Rockville, MD, http://www.lifetech.com) were used.
CAC Isolation and Migration
Mice were euthanized, tibias and femurs collected, flushed with ice-cold phosphate buffered 
saline (PBS) and made into single cell suspension. Cells were treated with ammonium 
chloride (Stem Cell Technologies, Vancouver, BC, Canada, http://www.stemcell.com) to 
remove erythrocytes and enriched for mouse hematopoietic stem/progenitor cells using 
negative selection kit, followed by Sca-1 positive selection (Stem Cell Technologies) to 
obtain Lin− Sca-1+ progenitor cells. Cells were maintained overnight at 37°C in 5% CO2 in 
humidified cell culture incubator, in endothelial cell growth medium (EGM-2) media with 
SingleQuot supplements and growth factors (Lonza, Allendale, NJ, USA, http://
www.lonza.com/). Cells were stained with Calcein-AM (BD Biosciences, San Diego, http://
www.bdbiosciences.com) and migration assay performed as described previously [13]. The 
cells isolated by this protocol were formerly called EPCs (endothelial progenitor cells). The 
terminology has now been updated to CACs, which is more reflective of the function of 
these cells [27].
Unilamellar Vesicle Formation
Unilamellar vesicles were formed by extrusion. Batch 1 was composed of 49 mol% dioleoyl 
phosphatidylcholine (DOPC), 1 mol% perylene, 10 mol% cholesterol, and 40 mol% 
sphingomyelin (chicken egg), and batch 2 of 49 mol% DOPC, 1 mol% perylene, 10 mol% 
cholesterol, 20 mol% sphingomyelin, 20 mol% ceramide. Perylene was purchased from 
Sigma Aldrich and other vesicle constituents from Avanti Polar Lipids (Alabaster, AL, USA 
http://www.avantilipids.com/). Constituents were present in chloroform or ethanol 
(perylene), aliquots were evaporated to dryness and taken up in 2.86 mL milli-Q water. The 
mixture was put through five freeze-thaw-vortex cycles and extruded 11 times through a 
polycarbonate filter [28]. The extruded vesicles were measured by DLS and were 
approximately 200 nm in diameter.
Membrane Fluidity Measurements
10,000 CACs were labeled with perylene [28] (10μM) for 15 minutes. Polarized 
fluorescence measurements were collected using time-correlated single-photon counting 
instrument, as described previously [28]. The instrument response function is approximately 
35 ps fwhm. Perylene emission transients (470 nm) were collected for polarizations parallel 
(III(t)) and perpendicular (I⊥(t)) to vertically polarized excitation pulse (435 nm). The 
polarized emission transients are used to construct the induced orientational anisotropy 
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decay function, r(t), which decays with a single exponential functionality and time constant 
of decay, τOR, is given by the modified Debye-Stokes-Einstein equation,
where η is viscosity of the medium, V is hydrodynamic volume of perylene (225 Å3), kBT is 
a thermal energy term, f and S are constants to account for frictional interactions between 
perylene and its surroundings, and the nonspherical shape of perylene. For all 
measurements, V, f, S, and T remain constant and changes in τOR reflect changes in η.
ASM Gene Inhibition
CACs were resuspended in electroporation solution (Lonza) to final concentration of 5 × 105 
cells per 100 μL, mixed with 300 nM ASM small interfering RNA (siRNA), and 
electroporated (Nucleofector program M-030, Lonza). Cells were maintained in 
supplemented medium at 37°C in 5% CO2 in humidified incubator for 48 hours. 
Approximately fivefold inhibition of ASM expression was obtained as determined by RT-
PCR and Western Blot.
Reendothelialization of Retinal Vasculature
10,000 Lin−Sca+gfp+ progenitor cells were injected intravitreously using 33-gauge 
(Hamilton Company, Reno, NV, USA, http://www.hamiltoncompany.com/), into diabetic 
and control WT mice. After 7 days to allow progenitor cells homing to retinal vessels, mice 
were sacrificed, eyes removed, pierced with a 30-gauge needle, fixed in 4% 
paraformaldehyde for 1 hour, and washed in PBS. Retinas were isolated and permeabilized 
overnight at 4°C in HEPES-buffered saline containing 0.1% Tween 20 and 1% bovine serum 
albumin (BSA). Vasculature was stained with rabbit anti-collagen IV (Abcam, Cambridge, 
U.K., http://www.abcam.com) diluted 1:400, followed by PBS wash. Secondary antibody 
chicken anti-rabbit (Alexa Fluor 594, Invitrogen, Carlsbad, CA, http://www.invitrogen.com), 
diluted 1:1,000 was used.
Immunofluorescent Staining
Ceramide in BM Cells—CACs were treated with anticeramide (Sigma Aldrich) antibody 
and corresponding secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA, 
https://www.thermofisher.com).
Microglia in the Retina—Retinal flat-mounts from gfp+ chimeras were stained for 
microglia using 1:100 diluted goat anti-Iba-1 (Novus Biologicals, Littleton, CO, USA, http://
www.novusbio.com/). BM-derived microglia cells were defined by gfp+, Iba-1+ staining and 
shape. Mean counts of Iba+ gfp+ cells were taken from three points within central retina at 
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×20 magnification. Length of primary dendrites of microglia was quantified using 
MetaMorph software. All measurements were done in a masked fashion. Nikon TE2000 
fluorescence microscope with Photometrics CoolSNAP HQ2 camera was used for imaging. 
Staining was quantified using MetaMorph software (Molecular Devices, Downingtown, PA, 
http://www.moleculardevices.com).
Transferase-Mediated Deoxyuridine Triphosphate (dUTP) Nick-End Labeling Staining
TACS-XL Basic In Situ Apoptosis Detection Kit (https://www.trevigen.com) was used on 
paraffin-embedded sections according to manufacturer's protocol. Number of terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in ganglion 
cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL) were counted, 
and data expressed per retina [20].
Morphometric Analysis
Retinal sections were stained with hematoxylin and eosin, and thickness of inner plexiform 
layer (IPL), INL, outer plexiform layer (OPL), and ONL was measured using images 
captured from four microscopic fields with Nikon TE2000 microscope and color camera. 
Calibrated lines were drawn perpendicular to each layer of the retina using Metamorph 
software, and average thickness of each retinal layer was expressed in μm.
Flow Cytometry
Flow cytometry was performed using LSR II instrument (BD Biosciences). Data were 
analyzed with FlowJo software (Tree Star, Oregon, USA, http://www.treestar.com/). 
Antibodies were purchased from eBioscience, San Diego, CA, USA, http://
www.ebioscience.com/.
Mass Spectrometry
One to five million cells were subjected to monophasic lipid extraction. High resolution 
mass spectra were acquired using a Thermo Scientific model LTQ Orbitrap Velos mass 
spectrometer (San Jose, CA, http://www.thermoscientific.com/) and Advion Triversa 
Nanomate nESI source (Advion, Ithaca, NY, http://www.advion.com/) as previously 
described [29].
Statistical Analyses
Data are presented as mean±SEM. Results were analyzed for statistical significance by 
Student's t test or one-way ANOVA followed by Tukey's or Bonferroni's post hoc test 
(GraphPad Prism5, GraphPad Software, San Diego, CA http://www.graphpad.com/), where 
appropriate.
Results
ASM-Deficiency in BM Prevents Inflammation in Diabetic Retina
To address the specific role of ASM in affecting BM cells, C57BL/6J mice were 
transplanted with ASM−/−, ASM−/−×gfp+, or WT age-matched BM. After 4 months to allow 
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stable reconstitution, mice were made diabetic with STZ injections. Table 1 shows body 
weights and blood glucose levels for diabetic and control chimeras. By 2 weeks after onset 
of diabetes, diabetic mice weighed significantly less and their blood glucose levels were 
significantly higher than control mice. ASM−/− → WT and WT → WT BM transplanted 
(BMT) diabetic mice had similar degree of diabetes throughout the study (Table 1).
Previous studies showed that diabetes causes accumulation of BM-derived monocytes in the 
retina. These monocytes adopt a microglia-like phenotype and contribute to retinal 
inflammation by secreting proinflammatory cytokines [5, 8, 9]. Microglial activation is 
usually identified by morphological changes, involving retraction of highly ramified 
processes and assuming amoeboid shape with thicker dendrites and larger cell bodies [30–
32]. We anticipated that ASM−/− phenotype in the diabetic BM may influence activation of 
BM-derived microglia-like population. To distinguish cells migrating to the retina from the 
BM, retinas from gfp+ ·WT and ASM−/−×gfp+ ·WT BM chimeras were examined after 3 
months of diabetes. Although no significant difference in numbers of BM-derived microglia-
like cells was observed in chimeric mice, more activation of BM-derived gfp+ microglia was 
seen in retinas of diabetic gfp+·WT BM chimeras. ASM−/−×gfp+·WT BMT prevented this 
increase in microglial activation in diabetic retinas (Fig. 1A), indicating that ASM 
upregulation in these cells may contribute to inflammation in the diabetic retina.
The pathogenesis of DR involves chronic low-grade inflammation, and studies show that 
activated glial cells may contribute to cytokine production in the diabetic retina [2, 30–32]. 
The twofold or less changes in inflammatory markers in the diabetic retina reported here are 
consistent with low-grade inflammation associated with DR [5]. ASM deficiency in BM 
prevented diabetes-associated upregulation of inflammatory markers and growth factors like 
IL-1β, VEGF, ASM, ICAM-1, and VCAM-1 in retina of chimeric mice after 2 months of 
diabetes (Fig. 1B).
In order to visualize retinal neuronal changes, we measured the thickness of the inner retinal 
layers and performed TUNEL staining of retinal sections. No gross differences in retinal 
structure and inner retinal thickness were observed in control, diabetic, and diabetic mice 
with ASM−/− BM at 8 weeks of diabetes, in agreement with a previous study [33]. The 
number of apoptotic neurons detected by TUNEL-positive cells was also similar in all 
groups (Supporting Information Fig. S1), which is in agreement with Feit-Leichman et al. 
showing that neuronal apoptosis does not change significantly at 2–3 months of diabetes in 
C57BL/6J strain, despite other evidences of retinal vascular pathology [34].
ASM-Deficiency in BM Improves CAC Release and Homing to Retinal Vasculature
Apart from giving rise to all blood cells, HSC in the BM also differentiate into reparative 
CACs, which circulate in blood and home to areas of injury to mediate vascular repair [35]. 
Accumulating evidence suggests that BM neuropathy affects CAC proliferation, release, and 
migration in diabetes [10]. We observed impaired release of CACs, leading to higher number 
of CACs in BM of 2 month-diabetic WT chimeras (Fig. 2A) as well as lower numbers of 
diabetic CACs in circulation (Fig. 2B), which was prevented in diabetic ASM−/− BM 
chimeras.
Chakravarthy et al. Page 7





















To directly assess effect of ASM inhibition in CACs on in vivo homing capacity, we injected 
gfp+-expressing CACs treated with ASM-siRNA into vitreous of 8–9 month diabetic WT 
mice. Approximately fivefold inhibition of ASM was achieved (Supporting Information Fig. 
S2). Seven days postinjection, retinas were analyzed for colocalization of retinal vasculature 
with gfp+ progenitor cells. When healthy CACs were injected into the vitreous of diabetic 
mice, we observed their participation in vessel repair as demonstrated by yellow color, due 
to colocalization of green (gfp+ CACs) and red (retinal vasculature staining) (Fig. 2C, left 
panel). Diabetic CACs lose this ability and do not migrate to the site of injury (Fig. 2C, 
middle panel); however, diabetic CACs after ASM inhibition participated in repair to similar 
levels as control CACs (Fig. 2C, right panel). These data indicate that specific inhibition of 
ASM in CACs restores their reparative capacity in a DR model.
ASM Inhibition Reduces Ceramide Levels in CACs and BM Cells
To assess effect of ASM deficiency on sphingolipid metabolism in BM cells, we 
characterized SM and ceramide species using mass spectra from lipid extracts of WT and 
ASM−/− BM cells and CACs. A dramatic increase in SM and concomitant decrease in 
ceramide was observed in ASM−/− BM cells and CACs compared to WT (Fig. 3A, 3B, Table 
2; Supporting Information Fig. S3).
Ceramide metabolites such as glucosylceramides, sphingosine, and S1P play important roles 
in insulin resistance, as well as cellular proliferation and migration [22, 36]. We examined 
the effect of ASM deficiency on ceramide metabolites in ASM−/− BM cells and CACs 
compared to WT. While we observed a decrease in some hexosylceramide species, we did 
not observe any significant differences in sphingosine or S1P levels (Table 2).
We next determined the effect of diabetes on CACs ceramide levels in WT and ASM−/− 
BMT mice. As limited amount of material isolated from these stably engrafted long term 
diabetic mice does not allow for detailed mass spectrometry analysis, we used an alternative 
immunohistochemistry method using anti-ceramide antibodies. Approximately 50% increase 
in ceramide level was observed in diabetic CACs. In contrast, ASM−/− BMT prevented this 
increase in ceramide levels in diabetic mice (Fig. 3C).
Ceramide Levels Alter Membrane Viscosity of Synthetic Vesicles and Progenitor Cells
Membrane deformability can be modulated by membrane lipid content [35, 37]. We first 
determined the effect of ceramide on membrane viscosity of artificial vesicles by replacing 
50% of SM with equal length ceramide in model lipid bilayers. To measure membrane 
viscosity, we labeled synthetic vesicles with a fluorescent probe, perylene (Fig. 4A)—
nonpolar polycyclic aromatic hydrocarbon that incorporates selectively into bilayer nonpolar 
region with well-characterized rotational diffusion behavior [28]. Viscosity of extruded 
synthetic vesicles was quantitated by rotational diffusion of perylene. We observed that 
replacing sphingomyelin with ceramide in synthetic vesicles caused a significant increase in 
viscosity of membranes (Fig. 4A). We then determined the effect of ceramide on membrane 
viscosity of CACs. Membrane viscosity decreases significantly in ASM−/− CACs, indicating 
that loss of ASM prevents cell membrane rigidity in CACs (Fig. 4B).
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ASM−/− BM Transfer Corrects Diabetes-Induced Deficiency in CAC Migration
Because migration of CACs is central to their function as reparative cells, we sought to 
understand if change in membrane rigidity due to ceramide is associated with diabetes-
induced reduction in CAC motility. Increased membrane rigidity in CACs isolated from 
mice at 3 months of diabetes correlates with their reduced migration ability. However, 
membrane rigidity was normalized in diabetic CACs from ASM−/− BM chimeras, which 
further correlated with improved migration ability (Fig. 4C, 4D).
Retinal Vascular Damage Is Prevented in Diabetic ASM−/− BM Chimeric Mice
We examined whether the combination of improved CAC migration and reduced activation 
of BM-derived inflammatory cells could prevent retinal vascular degeneration in diabetic 
ASM−/− BM chimeras. We observed increased vascular permeability as assessed by leakage 
of FITC-albumin compared to control chimeras, and this increase was prevented in diabetic 
ASM−/− BM chimeras (Fig. 5A).
Acellular capillaries are a histopathological hallmark of DR. We observed a significant 
increase in acellular capillaries in diabetic as compared to control WT BM chimeric mice 
(Fig. 5B). This increase was prevented in diabetic ASM−/− BM chimeras, supporting the 
hypothesis that ASM inhibition selectively in the BM is sufficient to protect from diabetes-
induced retinal vascular pathology.
Discussion
Landmark clinical trials, DCCT and ACCORD Eye demonstrated that control of 
hyperglycemia and dyslipidemia is required to achieve maximal protection from DR [18, 
19]. Although hyperglycemia-associated damage has been studied in detail, few studies 
addressed the effect of dyslipidemia in DR. Dyslipidemia is a complex metabolic 
dysregulation of multiple lipid classes including triglycerides, cholesterol, esterified and 
non-esterified fatty acids, and sphingolipids.
Previous studies by others and us indicated that dysregulation of sphingolipid metabolism, 
with upregulation of ASM and higher hexosyl ceramide production plays an important role 
in diabetic dyslipidemia-induced retinal damage [20, 22, 23]. However, whole-body ASM 
deficiency leads to retinal dysfunction and neurodegeneration in ASM−/− mice [38, 39]. A 
recent study by Dannhausen et al. demonstrates activation of microglia and loss of retinal 
function in ASM−/− mice [38].
In addition to previously reported direct retinal effects, ASM upregulation could also affect 
the BM niche, disturbing the balance between proinflammatory and reparative BM cell 
populations. This affords us an opportunity to inhibit ASM only in the BM cells, thus 
avoiding the unwanted neurodegenerative effects due to systemic ASM inhibition. To 
achieve selective BM inhibition in this study, we have generated chimeric mice by ASM−/− 
→ WT or WT → WT BM transplantation. BM transplantation ensures that all the cells 
derived from the BM are ASM deficient, while ASM activity is maintained in other tissues, 
including retina.
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Dysfunction of BM-derived CACs is a critical component of the pathogenic events 
associated with DR [40, 41]. Recent studies indicate that CACs isolated from diabetic 
patients are not effective in vascular regeneration due to impaired migration, proliferation, 
and differentiation [10, 12, 42]. Advanced diabetes is associated with BM neuropathy which 
contributes to the inability of CAC to egress the BM, enter the circulation, and home to areas 
of injury [43, 44]. Thus, this trapping of CACs within the BM makes these cells unavailable 
for vascular repair [10]. Furthermore, the migratory prowess of diabetic CACs is severely 
altered due to their inability to respond to hypoxia with an increase in hypoxia-inducible 
factor (HIF) expression or to migrate toward gradients of hypoxia regulated factors, such as 
VEGF-A and stromal derived factor-1 (SDF-1) [14, 45, 46]. The migratory defect of these 
cells is a result of reduced bioavailability of nitric oxide (NO) as well as poor deformability 
[14].
We have previously demonstrated that blocking upregulation of ASM in diabetic CACs leads 
to improved colony forming ability, indicating an improved capacity of these reparative cells 
to adhere and differentiate in culture [13]. Recently, ceramide metabolites such as C1P and 
S1P were found to upregulate SDF-1 secretion from BM stromal cells, potentially altering 
chemokine gradients that guide the release of progenitor cells from their BM niche [16, 47, 
48]. In our study, we demonstrate that increased ceramide levels alters membrane fluidity of 
diabetic CACs leading to impaired CAC release from the BM and reduced migration to areas 
of retinal vascular injury in a mouse model of DR.
In addition to reparative CAC dysfunction, diabetes affects BM-derived inflammatory 
myelomonocytic cells, which circulate in blood and contribute to diabetes-associated 
inflammation. Previous studies showed that diabetes causes accumulation of inflammatory 
monocytes in the retina [7, 11]. Proinflammatory BM-derived cells, like neutrophils and 
monocytes, were recently demonstrated to play important roles in retinal endothelial cell 
death and capillary degeneration in diabetes [7]. However, the exact contribution of BM-
derived microglia to retinal damage during diabetes remains unclear. During embryonic 
development, resident tissue microglia are known to develop from a yolk sac and do not 
have myeloid origin [49]. Several studies demonstrated that in normal tissue, microglial 
regeneration occurs from tissue-specific microglial progenitors [50]. This balance could shift 
toward myeloid cells with ageing, inflammation, or tissue damage [5, 9, 31]. We observed 
Iba+ gfp+ cells in control and diabetic retinas; however, Iba+ gfp+ cells in control retinas had 
branched resting phenotype compared to clearly activated amoeboid phenotype in diabetic 
retinas, indicating that diabetes-induced damage promotes myeloid-derived microglial 
activation. Furthermore, our data demonstrate that inhibition of ASM in BM prevents 
activation of these microglia-like cells. Reduced activation of BM-derived microglia may 
contribute to normalizing levels of proinflammatory cytokines and growth factors in retinas 
of diabetic ASM−/− BM chimeras.
In this study, we demonstrate that the combination of improved CAC migration and reduced 
activation of BM-derived inflammatory cells in ASM−/− BM chimeras prevents diabetes-
induced retinal vascular degeneration. Vascular degeneration characterized by increase in 
number of acellular capillaries is typically determined after 6 months of diabetes; however, 
BM transplantation and stable engraftment before the induction of diabetes resulted in older 
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age of mice at the end of the experiment (9–11 months old). Older age likely contributed to 
the high numbers of acellular capillaries that we observed at 3–5 months of diabetes (Fig. 
5B).
ASM activation and ceramide production can alter cell fate through a variety of mechanisms. 
ASM activation has been associated with increased cytokine release in the resident microglia 
of the retina [51]. Ceramide may serve as a second messenger in initiating apoptosis of 
endothelial cells, while reduction of ceramide levels by inhibiting ASM has been 
demonstrated to prevent endothelial cell death, leading to reduced capillary apoptosis in 
tumor microenvironments [52, 53]. Previously, we showed that inhibition of ASM by dietary 
supplementation of docosahexaenoic acid or by genetic manipulation prevents retinal 
vascular degeneration associated with diabetes [13, 20, 25]. However, as retinal effects of 
ASM−/− are also associated with neurodegeneration, in this study we wanted to separate the 
BM and retinal/vascular effects of ASM−/−. The retina and vasculature of the chimeric 
animals in this study were from the WT host, only the BM was from the ASM−/− mice. 
Thus, although in the whole body ASM−/− model endothelial cell death is inhibited, the 
model we used does not directly affect endothelial ASM expression levels and the effects we 
observed were mediated by changes in BM progenitors.
In this study, we explore the role of ceramide as a structural membrane component 
contributing to membrane fluidity. Ceramide has a tendency to self-associate, forming 
ceramide-enriched platforms in the cell membrane [54]. These altered membrane 
microdomains have been demonstrated to enhance inflammatory signal transduction by 
facilitating receptor clustering, thereby promoting survival and immune activation of a 
variety of immune cells including monocytes [54–56]. Here, we further explore the concept 
that altered membrane fluidity of diabetic CACs leads to their impaired release and 
migration, making them unavailable for vascular repair. These roles of ceramide are not 
conflicting—these effects are likely happening simultaneously with decreased membrane 
fluidity, endothelial cell apoptosis, and proinflammatory pathways contributing to 
pathogenesis of DR.
Various sphingolipids, such as glycosphingolipids, sphingosine, and S1P have been shown to 
play a role in development of DR [20–22, 24]. Ceramide can be metabolized into S1P, which 
has proliferation, migration, and prosurvival effects [35]. Elevated levels of S1P are shown 
to contribute to retinal vascular pathology in animal models of diabetes [21, 24]. However, 
we did not observe any changes in sphingosine or S1P levels in ASM−/− mouse BM cells or 
CACs, indicating that although these bioactive lipids may be involved in other aspects of 
diabetes-induced damage, they cannot explain the correction of deficient migration or 
normalization of proinflammatory pathways observed in ASM−/− BMT mice in this study.
Apart from the important role of ceramide in inflammatory responses, there is also a well-
established literature indicating that presence of ceramide and cholesterol in a lipid bilayer 
causes a change in “viscosity” of membranes [54, 57, 58]. We have previously demonstrated 
that diabetes is associated with reduced deformability of human CACs, this reduced 
deformability is associated with decreased migratory prowess [14] and that ASM activation 
leads to increased short-chain ceramide levels in diabetic CACs [13]. In this study, we show 
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that increased levels of membrane ceramide due to ASM activation in diabetes are 
associated with increased membrane rigidity, impaired migration and extravasation capacity 
of CACs, which in turn prevents effective homing from BM to sites of vascular injury.
Taken together, these data suggest that modifying membrane lipid composition of diabetic 
BM-derived cells may be beneficial for preventing retinal vascular degeneration. 
Conceivably, measure of membrane rigidity could be used in the clinic as a mechanical 
biomarker to gain evidence of ongoing biological stress and tissue damage due to diabetic 
dyslipidemia. Furthermore, correction of membrane rigidity can be explored as a potential 
treatment strategy to improve migration and repair function of CACs in diabetic patients. 
Intravenous infusion of autologous CACs corrected for membrane rigidity ex vivo could be 
used as a therapeutic strategy to enhance repair in vivo [15]. Cell therapy is ideal for 
treatment of diabetic patients as microvascular disease does not lend itself to 
revascularization procedures such as stents and angioplasty but is amenable to cell therapy. 
The interest in cell therapy is apparent as CD34+ cells are the most commonly used cells for 
human regenerative studies. There are 388 trials using CD34+ cells listed on Clinical 
Trials.gov, including one trial using these cells for retinal vascular repair in diabetes 
(NCT01736059).
Conclusion
In conclusion, we demonstrated that pathological activation of ASM in BM-derived cells 
plays a crucial role in diabetes-induced retinal vascular degeneration by activating 
microglia-like BM-derived cells that infiltrate the retina, and preventing efficient retinal 
vascular repair by reparative CACs. Our studies provide novel insights into the highly 
complex mechanisms that lead to retinal vascular degeneration in diabetes and suggest that 
strategies targeting normalization of ASM in BM-derived cell populations, thereby 
controlling the balance between reparative and proinflammatory cells could represent a 
viable cell therapy option to enhance available DR treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Diabetic retinopathy (DR) remains a challenge in clinical ophthalmology since current 
approaches for treatment are highly invasive and do not fully prevent or reverse 
pathology. Previous studies have demonstrated that bone marrow dysfunction in diabetes 
critically contributes to retinal vascular degeneration. We explore a novel concept that 
altered sphingolipid metabolism in the bone marrow plays a crucial role in diabetes-
induced retinal vascular degeneration by activating inflammatory cells that infiltrate the 
retina and preventing efficient retinal vascular repair by reparative cells. Our studies 
identify for the first time, that modulation of acid sphingomyelinase to control ceramide 
content in bone marrow cells, including therapeutic progenitor cells membranes can be a 
highly effective therapeutic target for correcting vascular degeneration associated with 
diabetic retinopathy.
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ASM deficiency in BM prevents inflammation in diabetic retina. (A): Microglial marker 
Iba-1+ staining (red) with gfp+ (green) cells, showing colocalization (yellow) in retina. 
Control retinas show gfp+ microglia with highly ramified phenotype (white arrow). Diabetic 
retinas show gfp+ microglia with retracted processes (white arrowhead). Diabetic retinas 
from ASM−/− BM chimeric mice show ramified phenotype (white arrow). Quantification of 
dendritic length of microglia is shown on the right. n=8 per group. ***, p<.001 relative to 
diabetic. Scale bar=50 μM. Duration of diabetes was 3 months. (B): Quantitative polymerase 
chain reaction for relative mRNA levels of indicated genes in diabetic retinas relative to 
controls. Duration of diabetes was 2 months. n=7–10 per group. *, p<.05; **, p<.01; ***, 
p<.001 relative to control. ##, p<.01; ###, p<.001 relative to diabetic. Data are expressed as 
means ± SEM for all. Abbreviations: ASM, acid sphingomyelinase; BM, bone marrow; 
IL-1β, interleukin-1β; VEGF, vascular endothelial growth factor; ICAM-1, intercellular 
adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; WT, wild-type.
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ASM inhibition improves CAC release and incorporation into retinal vasculature. (A): 
Percentages of CACs in BM of 2 months diabetic wild-type (WT) chimeric mice is 
increased compared to nondiabetic chimeras, and this is prevented in diabetic ASM−/− BM 
chimeras. n=4–8 per group, **, p<.01 relative to control; ##, p<.01 relative to diabetic. (B): 
Percentages of CACs in blood of 2 months diabetic WT chimeric mice is decreased 
compared to nondiabetic chimeras, and this is prevented in diabetic ASM−/− BM chimeras. 
n=4–8 per group, &, p=0.07 relative to control, #, p<.01 relative to diabetic. (C): Diabetic 
animals received intravitreal injections of control (left), diabetic (middle), or diabetic CACs 
treated with siRNA for ASM (right). CACs (green) were isolated from gfp+ mice, retinal 
vasculature was stained with anticollagen IV antibody (red), and colocalization (yellow) 
indicates vascular association. Diabetic CACs show reduced colocalization with vasculature 
(middle), while ASM inhibition improves vascular association of diabetic CACs (right). 
Quantification of colocalization (yellow) is shown on far right. Duration of diabetes was 8–9 
months. * p<.05 relative to diabetic. Data are expressed as means±SEM. Scale bars=50 μM. 
Abbreviations: ASM, acid sphingomyelinase; BM, bone marrow; CAC, circulating 
angiogenic cell.
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Effect of ASM inhibition on sphingolipid metabolism in BM cells and CACs. Total ceramide 
and ratio of total ceramide to total SM were significantly decreased, and total SM 
significantly increased in ASM−/− BM cells (A) and CACs (B). n=6 per group, **, p<.01; 
***, p<.001. Data are expressed as means±SD. (C): Immunofluorescence using 
anticeramide antibody (green) demonstrates that diabetic CACs from WT BM chimeras 
(middle) have increased ceramide levels compared to control CACs (left). This increase is 
prevented in diabetic CACs from ASM−/− BM chimeras (right). Scale bar=10 μM. 
Quantification of green fluorescence relative to DAPI nuclear stain is shown on far right. 
Duration of diabetes was 3 months. Data are expressed as means±SEM. n=4–5 per group. 
**, p<.01 relative to control; #, p<0.05 relative to diabetic. Abbreviations: BM, bone 
marrow; CAC, circulating angiogenic cell; SM, sphingomyelin; RFU, relative fluorescence 
units; WT, wild type.
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Change in ceramide and ASM levels alter membrane viscosity of diabetic CACs. (A): 
Replacing SM with ceramide increased viscosity of synthetic membranes. ***, p<.001, n=5 
per group. On Left: Extruded synthetic vesicle by electron microscopy. Data are expressed 
as means±SD. (B): CACs isolated from ASM−/− mice have decreased membrane viscosity 
compared to CACs from WT mice. n=4–5 per group, **, p<.01 relative to control. Data are 
expressed as means±SD. On left: Cells labeled with fluorescent probe, perylene. (C): 
Increase in membrane viscosity observed in diabetic CACs from WT chimeras was 
normalized in 3 months diabetic CACs from ASM−/− BM chimeras. Data are expressed as 
means±SD. n=4–5 per group. **, p<.01 relative to control; #, p<.05 relative to diabetic. (D): 
Migration toward SDF-1 is improved in diabetic CACs isolated from ASM−/− BM chimeras 
compared to diabetic CACs from WT chimeras. Data are expressed as means±SEM. n=5–7 
per group, **, p<.01 relative to control. #, p<.05 relative to diabetic. Duration of diabetes 
was 3 months. Abbreviations: ASM, acid sphingomyelinase; BM, bone marrow; CAC, 
circulating angiogenic cell; FBS, fetal bovine serum; PBS, phosphate buffered saline; SM, 
sphingomyelin; WT, wild type.
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Prevention of retinal vascular damage in diabetic ASM−/− BM chimeric mice. (A): Diabetic 
retinas (2 months duration) have increased vascular permeability compared to control as 
demonstrated by high retinal fluorescence intensity for FITC-albumin (middle). The increase 
is prevented in diabetic retinas from ASM−/− BM chimeric mice (right). Quantification of 
retinal fluorescence intensity for FITC-albumin is shown on far right. n=10–12 per group. 
Data are expressed as means±SEM. *, p<.05 relative to control and #, p=0.08 relative to 
diabetic. Scale bar=50 μM. (B): Increase in number of acellular capillaries (black arrows) in 
3–5 months diabetic retina (middle) is prevented in ASM−/− BM chimeras (right). 
Quantification of acellular capillaries is shown on far right. n=10–14 per group. Data are 
expressed as means±SD. ***, p<.001 relative to control and ##, p<.01 relative to diabetic. 
Scale bar=10 μM. Abbreviations: ASM, acid sphingomyelinase; BM, bone marrow; RFU, 
relative fluorescence units; WT, wild type.
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Table 1
Average body weights and nonfasting blood glucose levels of control and diabetic mice with WT or ASM−/− 
bone marrow transplantation
Duration of diabetes (weeks) Treatment group Blood glucose (mg/dL) Weight (g)
2 Control (WT bone marrow) 134±6.9 26±0.6
2 Diabetic (WT bone marrow) 361±19.3* 21.2±0.5*
2 Diabetic (ASM−/− bone marrow) 418±21.0* 22.6±0.7†
8 Control (WT bone marrow) 140±8.9 26.2±0.6
8 Diabetic (WT bone marrow) 427±46.6* 19.4±0.3*
8 Diabetic (ASM−/− bone marrow) 426±27.4* 18.9±0.6*
n=7–9, Data expressed as mean±s.e.m.
Abbreviations: ASM, acid sphingomyelinase; WT, wild type.
*Significantly different from age-matched control mice (p<.001).
†Significantly different from age-matched control mice (p<.01).
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Table 2
Sphingolipids in wildtype and ASM−/− mouse CAC and bone marrow cells
Lipid species (normalized 
abundance/106 cells)
Mouse CACs Mouse bone marrow cells
Wildtype ASM−/− Difference p Wildtype ASM−/− Difference P
Cer(d18:0/14:0) 0.24 0.75 0.280 0.36 0.32 0.896
Cer(d18:0/16:0) 0.68 1.11 0.412 1.13 0.69 0.309
Cer(d18:0/18:0) 0.11 0.13 0.829
Cer(d18:0/22:0) 0.07 0.04 0.155
Cer(d18:0/24:0) 0.05 0.01 ↓ 0.010
Cer(d18:1/14:0) 0.06 0.07 0.926
Cer(d18:1/16:0) 7.22 3.62 ↓ 0.002 6.48 4.18 ↓ 0.029
Cer(d18:1/18:0) 1.47 0.50 ↓ 0.011 0.48 0.29 0.050
Cer(d18:1/20:0) 0.17 0.07 0.102 0.10 0.06 0.139
Cer(d18:1/22:0) 2.07 0.33 ↓ 7.1e – 7 2.68 1.18 ↓ 0.002
Cer(d18:1/22:1) 0.08 0.06 0.576
Cer(d18:1/23:0) 0.37 0.03 ↓ 0.001 0.30 0.11 ↓ 0.032
Cer(d18:1/24:0) 6.00 1.17 ↓ 4.7e – 6 7.81 4.34 ↓ 0.009
Cer(d18:1/24:1) 10.83 3.27 ↓ 9.2e – 5 10.69 5.43 ↓ 0.001
Cer(d18:1/24:2) 4.81 0.85 ↓ 3.4e – 5 6.05 3.65 ↓ 0.011
Hex-Cer(d18:1/16:0) 2.09 0.54 ↓ 0.031 1.08 0.31 ↓ 0.004
Hex-Cer(d18:1/18:0) 0.43 0.05 0.264 0.10 0.08 0.732
Hex-Cer(d18:1/20:0) 0.44 0.13 0.278 0.16 1.21 0.388
Hex-Cer(d18:1/22:0) 2.42 1.03 ↓ 0.020 1.14 1.29 0.759
Hex-Cer(d18:1/24:0) 5.21 1.62 ↓ 1.1e – 5 3.13 1.02 ↓ 0.002
Hex-Cer(d18:1/24:1) 4.70 2.46 ↓ 0.043 2.13 0.92 ↓ 0.010
Hex-Cer(d18:1/24:2) 1.02 0.39 ↓ 0.022 0.55 0.33 0.127
SM(d18:0/14:0) 0.00 0.21 ↑ 0.039
SM(d18:0/16:0) 23.59 292.73 ↑ 2.4e – 6 29.30 181.15 ↑ 5.2e – 5
SM(d18:0/17:0) 0.01 0.91 ↑ 0.005
SM(d18:0/18:0) 0.83 30.59 ↑ 5.6e – 7 0.82 17.97 ↑ 6.3e – 5
SM(d18:1/14:0) 0.12 11.07 ↑ 4.8e – 5 0.10 6.11 ↑ 1.7e – 5
SM(d18:1/15:0) 1.33 15.97 ↑ 5.5e – 6 1.44 8.79 ↑ 0.0001
SM(d18:1/16:0) 330.12 3480.86 ↑ 5.2e – 6 371.04 2063.66 ↑ 5.1e – 5
SM(d18:2/16:0) 3.02 32.01 ↑ 7.2e – 6 2.85 18.02 ↑ 2.6e – 5
SM(d18:1/17:0) 3.09 24.15 ↑ 2.7e – 5 4.03 14.50 ↑ 0.002
SM(d18:1/18:0) 20.33 448.63 ↑ 2.1e – 6 14.57 252.65 ↑ 4.4e – 5
SM(d18:1/18:1) 0.10 13.23 ↑ 2.2e – 5
SM(d18:2/18:1) 0.43 23.95 ↑ 6.2e – 6 0.08 4.31 ↑ 2.8e – 8
SM(d18:2/18:2) 8.13 130.33 ↑ 0.002
SM(d18:1/19:0) 0.45 11.68 ↑ 5.7e – 6
SM(d18:1/20:0) 9.54 174.27 ↑ 2.7e – 6 7.23 100.65 ↑ 6.6e – 5
SM(d18:1/20:1) 0.12 16.21 ↑ 3.9e – 6 0.11 9.12 ↑ 5.4e – 5
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Lipid species (normalized 
abundance/106 cells)
Mouse CACs Mouse bone marrow cells
Wildtype ASM−/− Difference p Wildtype ASM−/− Difference P
SM(d18:2/20:1) 0.00 0.35 ↑ 2.8e – 6
SM(d18:1/21:0) 7.56 23.80 ↑ 0.002 9.17 15.63 0.160
SM(d18:1/22:0) 34.48 969.78 ↑ 1.9e – 6 43.07 606.24 ↑ 5.07e – 5
SM(d18:1/22:1) 4.62 171.11 ↑ 3.1e – 6 6.35 99.97 ↑ 5.4e – 5
SM(d18:2/22:1) 2.66 76.66 ↑ 1.1e – 5 3.52 43.41 ↑ 8.3e – 5
SM(d18:1/23:0) 7.04 154.43 ↑ 4.2e – 6 9.08 97.85 ↑ 0.0002
SM(d18:1/23:1) 1.19 41.09 ↑ 6.2e – 6 1.37 23.91 ↑ 0.0001
SM(d18:1/23:2) 0.12 2.11 ↑ 0.004
SM(d18:1/24:0) 46.63 1455.81 ↑ 1.6e – 6 76.79 947.45 ↑ 3.4e – 5
SM(d18:1/24:1) 185.69 2727.35 ↑ 3.2e – 6 252.45 1704.36 ↑ 6.3e – 5
SM(d18:1/24:2) 163.95 2687.45 ↑ 6.7e – 6 249.41 1654.85 ↑ 9.9e – 5
SM(d18:2/24:2) 7.41 83.78 ↑ 3.6e – 5
SM(d18:1/24:3) 5.32 149.91 ↑ 1.4e – 5
SM(d18:1/25:0) 0.08 28.25 ↑ 4.2e – 6 0.30 17.32 ↑ 6.3e – 5
SM(d18:1/25:1) 0.14 18.10 ↑ 1.0e – 5 0.22 10.64 ↑ 0.0001
SM(d18:1/25:2) 0.05 3.39 ↑ 0.001
SM(d18:1/26:0) 0.01 13.64 ↑ 5.5e – 6 0.03 8.30 ↑ 8.8e – 5
SM(d18:1/26:1) 0.13 21.16 ↑ 5.9e – 6 0.37 12.57 ↑ 5.7e – 5
SM(d18:1/26:2) 0.50 37.07 ↑ 7.5e – 6 1.61 22.38 ↑ 5.5e – 5
SM(d18:1/26:3) 0.28 48.13 ↑ 0.002
Sph16:0 5.32 8.65 ↑ 0.048 6.51 5.82 0.602
Sph16:0-P 0.00 0.00 0.061 0.00 0.01 0.149
Sph16:1 5.91 5.85 0.946 6.75 5.05 0.188
Sph16:1-P 0.00 0.00 0.585 0.00 0.01 0.439
Sph18:0 5.65 8.20 0.469 7.51 6.23 0.636
Sph18:0-P 0.00 0.01 0.377 0.00 0.01 0.269
Sph18:1 7.59 10.28 0.627 8.59 6.00 0.591
Sph18:1-P 0.01 0.00 0.845 0.01 0.01 0.844
Sph18:2 19.54 19.68 0.993 9.51 11.59 0.796
Sph18:2-P 0.00 0.00 0.653 0.00 0.00 0.054
Sph20:0 9.82 12.32 0.454 10.66 7.48 0.223
Sph20:0-P 0.00 0.00 0.223
Sph20:1 12.32 7.85 0.442 11.26 4.43 0.177
Sph20:1-P 0.05 0.00 0.196 0.05 0.02 0.405
Sph20:2 0.61 0.59 0.940 0.43 0.27 0.520
Sph20:2-P 0.00 0.01 0.488 0.01 0.00 0.434
Arrows pointing up indicate significant increase; arrows pointing down indicate significant decrease in ASM−/− as compared to wildtype.
Abbreviations: ASM, acid sphingomyelinase; CAC, circulating angiogenic cells; Cer, ceramide, Hex-Cer, hexosyl ceramide; SM, sphingomyelin; 
sph: sphingosine; sph-P: sphingosine phosphate.
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